Avalo Therapeutics Inc
$ 14.29
-2.52%
21 Apr - close price
- Market Cap 334,079,000 USD
- Current Price $ 14.29
- High / Low $ 14.75 / 14.12
- Stock P/E N/A
- Book Value 4.49
- EPS -5.84
- Next Earning Report 2026-05-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.34 %
- ROE -0.72 %
- 52 Week High 20.72
- 52 Week Low 3.39
About
Avalo Therapeutics Inc is a prominent clinical-stage biotechnology company focused on developing innovative therapies for rare and underserved diseases, particularly those involving immunological regulation. The firm has a robust pipeline of proprietary drug candidates aimed at addressing serious conditions with significant unmet medical needs, reflecting its commitment to advancing healthcare solutions. Avalo's deep expertise in disease mechanisms and comprehensive clinical trial methodologies position it strategically within the biopharmaceutical landscape, enabling the development of transformative therapies. With a strong patient-centric approach, Avalo is poised to enhance therapeutic outcomes and drive meaningful impacts in the lives of patients.
Analyst Target Price
$40.09
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-23 | 2025-11-06 | 2025-08-07 | 2025-05-12 | 2025-03-27 | 2024-11-07 | 2024-08-12 | 2024-05-13 | 2024-03-28 | 2023-11-09 | 2023-08-03 | 2023-05-04 |
| Reported EPS | -0.37 | -2.19 | -1.92 | -1.2867 | -2.74 | -1.25 | -14.07 | -141 | -116.21 | -0.11 | -0.59 | -0.85 |
| Estimated EPS | -1.495 | -1.22 | -1.19 | -1.605 | 1.665 | -1.19 | -6.7 | -1.18 | -4.8 | -1.1 | -0.8 | -0.97 |
| Surprise | 1.125 | -0.97 | -0.73 | 0.3183 | -4.405 | -0.06 | -7.37 | -139.82 | -111.41 | 0.99 | 0.21 | 0.12 |
| Surprise Percentage | 75.2508% | -79.5082% | -61.3445% | 19.8318% | -264.5646% | -5.042% | -110% | -11849.1525% | -2321.0417% | 90% | 26.25% | 12.3711% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-11 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 1.0 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AVTX
2026-04-18 02:10:09
AVALO THERAPEUTICS INC (AVTX) currently trades at $14.43, with analysts forecasting an average price target of $40.46, representing a potential upside of 180.39%. The stock has a strong buy consensus rating of 87.06% based on 17 analyst forecasts. The next earnings report is anticipated on May 11, 2026, with an estimated EPS of -$1.10 and $0 revenue.
2026-04-16 15:09:22
Wedbush has reiterated its Buy rating on Avalo Therapeutics (AVTX.US) and maintained its price target of $29. This indicates a continued positive outlook from the firm regarding the company's stock performance.
2026-04-15 12:40:34
Avalo Therapeutics (NASDAQ:AVTX) experienced a 35.5% increase in short interest as of March 31st, reaching 5,542,400 shares, which represents 25.1% of its shares sold short. Despite the significant short interest, analysts maintain a "Moderate Buy" consensus rating with an average target price of $44.83, while the stock currently trades near $13.90. However, insider selling has been noted, even as institutional ownership remains high at over 87%.
2026-04-13 17:40:02
BTIG analyst Julian Harrison has reiterated a "Buy" rating for Avalo Therapeutics (AVTX) and maintained a $40 price target, suggesting significant upside potential despite the stock's current trading value. However, GuruFocus indicates AVTX is 136500.0% overvalued with a GF Value™ of $0.01 and a low GF Score™ of 39/100, reflecting weaknesses in profitability and valuation. Insider selling activity further presents a mixed picture for investors, advising caution despite the analyst's optimism.
2026-04-10 19:39:18
Avalo Therapeutics (NASDAQ: AVTX) has scheduled its 2026 Annual Meeting of Stockholders for June 2, 2026, which will be held virtually. Shareholders will vote on the election of seven directors, the approval of a Second Amended and Restated 2016 Employee Stock Purchase Plan (ESPP) with changes including an annual share increase cap and extended "evergreen" feature, and the ratification of Ernst & Young LLP as its independent auditor. The proposed ESPP amendments aim to maintain its qualification under Section 423 of the Internal Revenue Code and align with employee compensation strategies.
2026-04-10 07:10:35
Wolfe Research has initiated coverage of Avalo Therapeutics (AVTX) with an "outperform" recommendation. This suggests a positive outlook from the firm regarding AVTX's stock performance.
